

**London, 17 July 2023** - Hikma Pharmaceuticals PLC (Hikma, Group), will announce its interim financial results for the six months ended 30 June 2023 on Thursday 3 August 2023.

A recording of the presentation will be available on the Group's website at [www.hikma.com](http://www.hikma.com) from 7:00am BST. Hikma will also hold a live Q&A conference call for analysts at 9:30am BST, and a recording will be made available on the Company's website.

To join via conference call please dial:

United Kingdom (local): +44 20 4587 0498

United Kingdom (toll-free): +44 800 358 1035

[Global Dial-In Numbers](#)

**Access Code: 317158**

For further information please contact Tiina Lugmayer - [tlugmayer@hikma.com](mailto:tlugmayer@hikma.com).

- ENDS -

## Enquiries

### Hikma Pharmaceuticals PLC

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 (0)7776 477050
Guy Featherstone Associate Director, Investor Relations	+44 (0)20 3892 4389/ +44 (0)7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 (0)7970 709912

### Teneo

Charles Armitstead	+44 (0)7703 330 269
--------------------	---------------------

## About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,800 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORGZGMNRRNGFZG